Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.32 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.30 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19082009 | 0.85 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL18268656 | 0.83 | PGR (0.33) | PGRPLA2G2APLA2G4AESR1ESR2 | |
| SCHEMBL19076868 | 0.83 | PGR (0.36) | PGRPLA2G2APLA2G4AESR1ESR2 | |
| SCHEMBL19082203 | 0.81 | PTPN1 (0.35) | ESR1ESR2LIMK1 | |
| SCHEMBL19076851 | 0.81 | TDP1 (0.34) | ESR1ESR2CYP1A1CYP1A2ABCG2 | |
| SCHEMBL19076673 | 0.81 | PLA2G2A (0.35) | PGRPLA2G2APLA2G4AESR1ESR2 | |
| SCHEMBL19076744 | 0.81 | PLA2G2A (0.33) | PLA2G2APLA2G4ALIMK1CYP1A1CYP1A2 | |
| SCHEMBL19082205 | 0.81 | TNKS (0.39) | ESR1ESR2LIMK1CYP1A1 | |
| SCHEMBL18842451 | 0.81 | TNKS (0.40) | PLA2G2APLA2G4AESR1ESR2ABCG2 | |
| SCHEMBL19082030 | 0.80 | ESR1 (0.32) | ESR1ESR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10553800-B2 | Condensed cyclic compound and an organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-02-04 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10553800-B2 | Condensed cyclic compound and an organic light-emitting device including the same | CRY1, CRY2, CCNT1 | PGR 1721/4885PLA2G2A 4330/4885PLA2G4A 4338/4885 |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNT1 | PGR 1721/4885PLA2G2A 4330/4885PLA2G4A 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.